| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23028 |
| Drug |
Mavacamten |
| Brand |
Camzyos® |
| Indication |
Mavacamten (Camzyos®) is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II–III), obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. |
| Rapid review commissioned |
19/05/2023 |
| Rapid review completed |
27/06/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mavacamten compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
26/07/2023 |
| Pre-submission consultation with Applicant |
12/09/2023 |
| Full submission received from Applicant |
20/12/2023 |
| Preliminary review sent to Applicant |
16/07/2024 |
| NCPE assessment re-commenced |
14/08/2024 |
| Factual accuracy sent to Applicant |
12/12/2024 |
| NCPE assessment re-commenced |
19/12/2024 |
